Home> Trial Details

Information Clinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.Learn why

Optimise reading forHealth Professionals Patients

RecruitingLast updated:25 November 2022

This phase I trial is evaluating a new targeted cancer drug in patients with Non-Hodgkin's Lymphoma who have got worse or not responded to prior treatmentAn Open-Label, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Antitumor Activity of RO7227166 (a CD19 Targeted 4-1BB Ligand) in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab Administered in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Clinical summary Eligibilty Participating hospital Support

Clinical summary

Summary

This trial has three parts, to which eligible patients will be assigned: dose escalation (Parts 1 and 2) and dose expansion (Part 3). Eligible patients will receive intravenous RO7227166 in combination with obinutuzumab and glofitamab. A fixed dose of obinutuzumab will be administered seven days prior to the first administration of RO7227166 and seven days prior to the first administration of glofitamab.

Age

People 18+

Phase

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

NCT04077723

Commercial Sponsor

Hoffmann-La Roche

Scientific Title

An Open-Label, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Antitumor Activity of RO7227166 (a CD19 Targeted 4-1BB Ligand) in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab Administered in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Share with email

Print this page

Download brochure

Eligibility

Inclusion

You have certain types of non-cancer medical conditions.
You have been diagnosed with a prior or secondary type of cancer.
You have had certain treatments, surgical procedures or drugs.
You have previously been treated (or are currently being treated) on a clinical trial.

Exclusion

You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

Information Tell us if you find this trial availability is not accurate.Report inaccuracy